Industry | Biotechnology, Pharmaceutical |
---|---|
Founded | 2021 |
Founder | PPF Biotech Group |
Headquarters | , |
Key people | Luděk Sojka |
Revenue | 231,110,000 Czech koruna (2020) |
−2,299,588,000 Czech koruna (2020) | |
−2,360,838,000 Czech koruna (2020) | |
Total assets | 7,736,322,000 Czech koruna (2020) |
Number of employees | 80 |
Website | https://www.sctbio.com |
SCTbio [1] [2] is global contract development and manufacturing organization ( CDMO) providing cGMP services of Advanced Therapy Medicinal Products ( ATMPs). It operates in Europe and North America. The company has strong expertise in the development of autologous cell-based products, cell banking and all needle-to-needle GMP operations, including a validated apheresis collection sites network, product manufacturing, QC, GMP storage, QA/QP release, and worldwide drug products supply for clinical and commercial scale. [3]
SCTbio was founded in 2021 and is a part of the larger PPF Biotech network. SCTbio was initially part of the SOTIO group, providing drug development and manufacturing capabilities. On July 1, 2021, SOTIO implemented an official split into two sister companies, SCTbio and SOTIO Biotech. [4] [1]
SCTbio conducts global operations in Europe and in the USA. The cGMP cell manufacturing facility is based in Prague, Czech Republic. The GMP facility features over 2,000 square meters of total space, including 420 square meters of total clean room area (4,520 sq ft). SCTbio offers the ability to of manufacture genetically modified products that require the separation of viral and non-viral components. The physical segregation minimizes any risk of cross-contamination.
SCTbio is led by CEO, Luděk Sojka, [8] who previously served as the COO and CTO of SOTIO. Through his time at SOTIO he was responsible for creating the SOTIO GMP facilities in Prague, Czech Republic and Beijing, China. He has been part of the PPF Biotech network and SOTIO since 2011. [9] [10]
Industry | Biotechnology, Pharmaceutical |
---|---|
Founded | 2021 |
Founder | PPF Biotech Group |
Headquarters | , |
Key people | Luděk Sojka |
Revenue | 231,110,000 Czech koruna (2020) |
−2,299,588,000 Czech koruna (2020) | |
−2,360,838,000 Czech koruna (2020) | |
Total assets | 7,736,322,000 Czech koruna (2020) |
Number of employees | 80 |
Website | https://www.sctbio.com |
SCTbio [1] [2] is global contract development and manufacturing organization ( CDMO) providing cGMP services of Advanced Therapy Medicinal Products ( ATMPs). It operates in Europe and North America. The company has strong expertise in the development of autologous cell-based products, cell banking and all needle-to-needle GMP operations, including a validated apheresis collection sites network, product manufacturing, QC, GMP storage, QA/QP release, and worldwide drug products supply for clinical and commercial scale. [3]
SCTbio was founded in 2021 and is a part of the larger PPF Biotech network. SCTbio was initially part of the SOTIO group, providing drug development and manufacturing capabilities. On July 1, 2021, SOTIO implemented an official split into two sister companies, SCTbio and SOTIO Biotech. [4] [1]
SCTbio conducts global operations in Europe and in the USA. The cGMP cell manufacturing facility is based in Prague, Czech Republic. The GMP facility features over 2,000 square meters of total space, including 420 square meters of total clean room area (4,520 sq ft). SCTbio offers the ability to of manufacture genetically modified products that require the separation of viral and non-viral components. The physical segregation minimizes any risk of cross-contamination.
SCTbio is led by CEO, Luděk Sojka, [8] who previously served as the COO and CTO of SOTIO. Through his time at SOTIO he was responsible for creating the SOTIO GMP facilities in Prague, Czech Republic and Beijing, China. He has been part of the PPF Biotech network and SOTIO since 2011. [9] [10]